We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.
- Authors
Irimia, Ruxandra; Barbu, Sinziana; Popa, Codruta; Badelita, Sorina
- Abstract
Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin.
- Subjects
T cells; AUTOIMMUNE hemolytic anemia; HODGKIN'S disease; LYMPHOMAS; IDIOPATHIC thrombocytopenic purpura
- Publication
Hematology Reports, 2023, Vol 15, Issue 1, p220
- ISSN
2038-8322
- Publication type
Case Study
- DOI
10.3390/hematolrep15010023